CCC
Cilo Cybin Holdings Limited cultivates, manufactures, and sells medical cannabis products worldwide. The company offers CBD, THC, and THCV distillates; THC and CBD crude; CBD, CBG, and CBN isolates; CBD Nano Oil; oil in bottles, cannabis flower, and cannabis vapes; and topicals, capsules, and device products. It also provides flower sourcing, formulation, manufacturing, and primary and secondary … Read more
CCC (CCC) - Net Assets
Latest net assets as of September 2025: R100.17 Million ZAR
Based on the latest financial reports, CCC (CCC) has net assets worth R100.17 Million ZAR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R108.94 Million) and total liabilities (R8.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R100.17 Million |
| % of Total Assets | 91.95% |
| Annual Growth Rate | 1688.63% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2765.06 |
CCC - Net Assets Trend (2022–2025)
This chart illustrates how CCC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CCC (2022–2025)
The table below shows the annual net assets of CCC from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | R57.34 Million | +10.09% |
| 2024-03-31 | R52.08 Million | +9708.87% |
| 2023-03-31 | R-542.00K | -5520.04% |
| 2022-03-31 | R10.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to CCC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68228500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | R58.02 Million | 101.19% |
| Total Equity | R57.34 Million | 100.00% |
CCC Competitors by Market Cap
The table below lists competitors of CCC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vissem Electronics Co. Ltd
KQ:072950
|
$24.73 Million |
|
Aegis Critical Energy Defence Corp.
F:JG6
|
$24.73 Million |
|
Firefly Neuroscience, Inc.
NASDAQ:AIFF
|
$24.73 Million |
|
Eclatorq Technology Co. Ltd.
TWO:6855
|
$24.75 Million |
|
Aztek Teknoloji Urunleri Ticaret A.S.
IS:AZTEK
|
$24.72 Million |
|
ALXPF
PINK:ALXPF
|
$24.72 Million |
|
PLASTIQ.V.LOI.INH.EO -90
F:1R9
|
$24.70 Million |
|
Proteomics International Laboratories Ltd
AU:PIQ
|
$24.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CCC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 52,080,472 to 57,335,067, a change of 5,254,595 (10.1%).
- Net loss of 585,716 reduced equity.
- Share repurchases of 627,712 reduced equity.
- Other factors increased equity by 6,468,023.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R-585.72K | -1.02% |
| Share Repurchases | R627.71K | -1.09% |
| Other Changes | R6.47 Million | +11.28% |
| Total Change | R- | 10.09% |
Book Value vs Market Value Analysis
This analysis compares CCC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 240.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1413256.33x to 240.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | R0.00 | R199.00 | x |
| 2023-03-31 | R-0.01 | R199.00 | x |
| 2024-03-31 | R0.81 | R199.00 | x |
| 2025-03-31 | R0.83 | R199.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CCC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-1.02%) is below the historical average (-0.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | R-497.80K |
| 2024 | 0.87% | 0.00% | 0.00x | 1.21x | R-4.75 Million |
| 2025 | -1.02% | 0.00% | 0.00x | 1.09x | R-6.32 Million |
Industry Comparison
This section compares CCC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $14,516,026,500
- Average return on equity (ROE) among peers: 18.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CCC (CCC) | R100.17 Million | 0.00% | 0.09x | $24.72 Million |
| Aspen Pharmacare Holdings Ltd (APN) | $28.88 Billion | 17.34% | 1.86x | $27.13 Million |
| Labat Africa Ltd (LAB) | $155.95 Million | 19.49% | 0.79x | $44.25K |